Q1 FY2027 · ended Sep 30, 2026 · Revenue $1.41B, +5.9% YoY · Filed Oct 30, 2026
ResMed Inc. (RMD) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q1 of fiscal 2027, the quarter ended Sep 30, 2026, it reported revenue of $1.4 billion and net income of $418.4 million. Free cash flow was $373.7 million. As of Sep 30, 2026 it held $1.0 billion in cash and investments and $770.6 million in total debt.
Revenue
$1.41B
+5.9% vs year-ago quarter
Net income
$418.41M
+20.0% vs year-ago quarter
Operating cash flow
$422.42M
-7.6% vs year-ago quarter
Free cash flow
$373.68M
-9.8% vs year-ago quarter
EPS
$2.92
+23.2% vs year-ago quarter
Dividend per share
$0.66
+10.0% vs year-ago quarter
Shares outstanding
140.66M
-3.6% vs year-ago quarter
Net cash
$240.19M
Q1 FY2027
Operating margin
33.0%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RMD (NYSE), RSMDF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 943819
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
- West Pharmaceutical Services Inc WST
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Sep 30, 2026 |
Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.5B | $1.4B | $1.4B | $1.3B |
| Operating income | $453.0M | $448.7M | $499.8M | $491.7M | $446.5M |
| Net income | $418.4M | $383.4M | $398.7M | $392.6M | $348.5M |
| Diluted EPS | $2.92 | $2.64 | $2.74 | $2.68 | $2.37 |
| Operating cash flow | $422.4M | $454.6M | $554.1M | $339.7M | $457.3M |
| Free cash flow | $373.7M | $403.5M | $520.5M | $311.2M | $414.4M |
| Total assets | $8.2B | $9.0B | $8.8B | $8.5B | $8.3B |
| Total liabilities | $2.3B | $2.4B | $2.3B | $2.2B | $2.2B |
| Stockholders' equity | $5.9B | $6.6B | $6.5B | $6.3B | $6.1B |
| Cash and investments | $1.0B | $1.5B | $1.7B | $1.4B | $1.4B |
| Total debt | $770.6M | $1.1B | $1.1B | $1.1B | $1.1B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| ARS | Annual report to shareholders | Oct 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Sep 1, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Auditor change, Officer or director change, Regulation FD disclosure
|
Aug 17, 2026 | Aug 13, 2026 |
| 10-K | Annual report | Aug 13, 2026 | Jun 30, 2026 |
All 1004 ResMed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.